BS_2EMW8ZG3
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 0.8541392904073587
- age_years
- 13.079
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.531
- ADIPOGENESIS+0.431
- BILE_ACID_METABOLISM+0.425
- PROTEIN_SECRETION+0.415
- NOTCH_SIGNALING+0.403
- FATTY_ACID_METABOLISM+0.378
- INTERFERON_ALPHA_RESPONSE+0.375
- INTERFERON_GAMMA_RESPONSE+0.371
- XENOBIOTIC_METABOLISM+0.336
- COMPLEMENT+0.301
Top 10 suppressed
- G2M_CHECKPOINT-0.458
- E2F_TARGETS-0.441
- MYC_TARGETS_V2-0.304
- MYC_TARGETS_V1-0.230
- MITOTIC_SPINDLE-0.222
- SPERMATOGENESIS-0.155
- UNFOLDED_PROTEIN_RESPONSE-0.140
- TGF_BETA_SIGNALING-0.127
- DNA_REPAIR-0.100
- WNT_BETA_CATENIN_SIGNALING-0.063
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15030885 | — | — | 0.872 |
| 2 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.870 |
| 3 | BS_8Z3SCKB5 | subependymal giant cell astrocytoma(SEGA) | — | 0.866 |
| 4 | SRR8518286 | — | F | 0.866 |
| 5 | BS_3W07B2TG | subependymal giant cell astrocytoma(SEGA) | — | 0.865 |
| 6 | BS_HV8PFRBR | pilocytic astrocytoma | — | 0.857 |
| 7 | BS_F4E8R9VY | Ganglioglioma | — | 0.856 |
| 8 | BS_X16PENSA | pilocytic astrocytoma | — | 0.855 |
| 9 | 6E2BE9AA-5DB6-45A4-80E0-C20F074C6CE6 | — | — | 0.854 |
| 10 | BS_T4JFN54G | low-grade glioma | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.531 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.431 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.425 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.415 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.403 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.378 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.375 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.371 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.336 | Inavolisib | — uncovered |
| COMPLEMENT | 0.301 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.268 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.254 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.246 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.242 | Inavolisib | — uncovered |
| PEROXISOME | 0.241 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.239 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.237 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.233 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.227 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.225 | Inavolisib | — uncovered |